TB-500
Synthetic fragment of Thymosin β4. Reported for recovery; small clinical trials in cardiac and ophthalmic contexts.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: Thymosin Beta-4 fragment
Synthetic fragment of Thymosin β4. Reported for recovery; small clinical trials in cardiac and ophthalmic contexts.
Evidence Intelligence Score™
- Preclinical← current
- Pilot human
- RCT
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data3.8
- Safety maturityFollow-up depth and adverse-event signal2.6
- Mechanism confidencePathway specificity and clarity6.5
- Clinical readinessDistance to physician-prescribable use2.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows1.8
- Translational confidenceAnimal → human signal preservation4.5
Mechanistic and preclinical evidence is suggestive; controlled human trials are not yet on the index.
Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: speculative. A grade upgrade requires controlled human evidence, not additional preclinical confirmation.
Tissue & joint repair
2 studies- moderateGoldstein AL, Kleinman HKPreclinical2012unreviewed
- moderateCrockford D, Turjman N, Allan C, Angel JPreclinical2010unreviewed
Recovery time
1 study- weakSosne G, Kim C, Kleinman HKPreclinical2012unreviewed
Tissue & joint repair
1 regimenInvestigational drug; safety profile in trials was favorable but TB4 is not approved for general use. 'TB-500' research peptides are not the same regulated preparation.
All studies were investigational and time-limited.
Recovery time
1 regimenAnimal model. 'TB-500' research peptide is not the same as clinical-grade Tβ4 (RGN-259).
Preclinical only.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
3 brands across three tiers.
Research-use only
3 brandsSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.